The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma
It is uncertain if different immunomodulatory drugs (IMID) pose distinct thrombotic risk in patients with newly diagnosed multiple myeloma (MM). Among 2397 MM patients from the SEER-Medicare database from 2007 to 2013, 78% received lenalidomide, and 22% received thalidomide. After inverse probability weighting to balance confounders, the 12-month incidences of venous thromboembolism (VTE 10%) and arterial thromboembolism (ATE 5%) were similarly high in both groups. Lenalidomide versus thalidomide had a subdistribution hazard ratio of 1.11 (0.59–2.02) for VTE and a subdistribution hazard ratio of 0.96 (0.45–1.98) for ATE. Overall survival was not significantly different with a hazard ratio of 0.88 (0.60–1.18) for lenalidomide versus thalidomide. Concurrent anticoagulant prophylaxis was infrequently prescribed in < 20% of both groups. Our study demonstrates that despite improvement in myeloma-directed therapy and supportive care, thrombosis remains an important consideration for all IMID-treated MM patients. Appropriate risk stratification and vigilant thromboprophylaxis remain essential to prevent this complication.
KeywordsMultiple myeloma Thromboembolism Venous thrombosis Arterial thrombosis
AL performed the research, designed the study, analyzed the data, and wrote the paper. DAG and GHL performed the research, designed the study, and wrote the paper. QW and GW analyzed the data. SL and ENL contributed essential tools and wrote the paper.
Compliance with ethical standards
Conflict of interest
The current study itself was conducted without funding from industry. AL reports grant funding from the Conquer Cancer Foundation Young Investigator Award, Hemostasis and Thrombosis Research Society Mentored Research Award supported by an independent medical educational grant from Shire, and National Hemophilia Foundation Shire Clinical Fellowship Award. Other authors report no relevant financial interests, activities, relationships, or affiliations.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Statement of informed consent
Informed consent was not obtained because this was a de-identified aggregate national claims database study where individual patient could not be identified and informed consent could not be obtained. The study was reviewed and considered exempt by the University of Washington Institutional Review Board.
- 2.Carrier M, Le Gal G, Tay J et al (2011) Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis. J Thromb Haemost 9:653–663. https://doi.org/10.1111/j.1538-7836.2011.04215.x CrossRefPubMedGoogle Scholar
- 3.White RH, Garcia M, Sadeghi B, Tancredi DJ, Zrelak P, Cuny J, Sama P, Gammon H, Schmaltz S, Romano PS (2010) Evaluation of the predictive value of ICD-9-CM coded administrative data for venous thromboembolism in the United States. Thromb Res 126:61–67. https://doi.org/10.1016/j.thromres.2010.03.009 CrossRefPubMedGoogle Scholar
- 4.Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99–104. https://doi.org/10.1016/j.ahj.2004.02.013 CrossRefPubMedGoogle Scholar
- 7.National Cancer Institute NCI Comorbidity Index. https://healthcaredelivery.cancer.gov/seermedicare/considerations/comorbidity.html
- 9.Chrischilles EA, Winiecki SK, Carnahan RM, et al. Mini-sentinel assessment protocol thromboembolic events after immunoglobulin administration. https://www.sentinelinitiative.org/vaccines-blood-biologics/assessments/thromboembolic-events-after-immunoglobulin-administration
- 10.Cancer Research Network Cancer Therapy Look-up Tables. https://crn.cancer.gov/resources/codes.html
- 13.National Comprehensive Cancer Network (2018) Cancer-associated venous thromboembolic disease. VTE-A2Google Scholar
- 14.Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Kumar S, Dispenzieri A, Mikhael JR, Bergsagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca R, Kyle RA, Greipp PR, Stewart AK, Rajkumar SV (2010) Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 115:1343–1350. https://doi.org/10.1182/blood-2009-08-239046 CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Luo J, Gagne JJ, Landon J, Avorn J, Kesselheim AS (2017) Comparative effectiveness and safety of thalidomide and lenalidomide in patients with multiple myeloma in the United States of America: a population-based cohort study. Eur J Cancer 70:22–33. https://doi.org/10.1016/j.ejca.2016.10.018 CrossRefPubMedGoogle Scholar
- 16.Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ, UK NCRI Haemato-oncology Clinical Studies Group (2019) Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 20:57–73. https://doi.org/10.1016/S1470-2045(18)30687-9 CrossRefPubMedPubMedCentralGoogle Scholar